Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win

What’s more, heading into its announcement, Alnylam’s market worth exceeded that of many large-cap drugmakers, at least in terms of sales and earnings multiples, noted Stifel’s Paul Matteis. The company was in a “trickier” spot than usual as a result.Alnylam also disclosed a subpoena related to its government price reporting. There were no allegations of wrongdoing, but the news pushed shares down, wrote Jefferies analyst Maury Raycroft, after speaking with executives.Mani Foroohar, of Leerink Partners, wro ...